Hepatitis C Articles



Natural History of Liver Cirrhosis Due to Hepatitis C

Past research has shown that a proportion of patients with chronic hepatitis C go on to develop progressive liver disease including advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) over a period of 10-40 years.

A study published in the June 2006 issue of Hepatology provided further information about the long-term progression of hepatitis C-related liver damage.

The researchers analyzed data from a cohort of 214 patients with compensated hepatitis C-related cirrhosis who were prospectively followed for 17 years. The patients had Child-Pugh class A cirrhosis and no previous clinical decompensation. Follow-up included periodic clinical and abdominal ultrasound examinations.

Results

Over 114 months of follow-up (range 1-199), observed evidence of liver disease progression was as follows:
- HCC developed in 68 patients (32%); annual incidence rate 3.9%
- ascites in 50 patients (23%); annual incidence rate 2.9%
- jaundice in 36 patients (17%); annual incidence rate 2.0%
- upper gastrointestinal bleeding in 13 patients (6%); annual incidence rate 0.7%
- encephalopathy in 2 patients (1%); annual incidence rate 0.1
Clinical status remained unchanged in 154 patients (72%); 45 patients (21%) progressed to Child-Pugh class B and 15 patients (7%) progressed to class C.
HCC was the first complication to develop in 58 patients (27%), followed by ascites in 29 patients (14%), jaundice in 20 patients (9%), and upper gastrointestinal bleeding in 3 patients (1%).
HCC was the major cause of mortality, responsible for 44% of deaths
The annual mortality rate was 4.0% per year, and was higher in patients who had additional potential causes of liver disease (5.7% vs 3.6%; P = .04).
Among the groups with persistently normal, currently high, and

Conclusion

The authors concluded that hepatitis C-related cirrhosis is a "slowly progressive disease that may be accelerated by other potential causes of liver disease." HCC was the first complication to develop, and the dominant cause for increased mortality.

6/16/06

Reference
A Sangiovanni, GM Prati, P Fasani, and others. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43(6): 1303-1310. June 2006.



Google


FDA-approved Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron

FDA-approved Combination Therapies for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin